Grade 3 or 4 toxicities
| Adverse event . | No. of patients (n = 21) . | % . |
|---|---|---|
| Sepsis | 2 | 10 |
| Duodenal perforation | 2 | 10 |
| Cystic fluid collection | 2 | 10 |
| Hyperlipasemia | 2 | 10 |
| Hyperamylasemia | 1 | 5 |
| Elevated liver tests | 1 | 5 |
| Fever | 1 | 5 |
| Leukopenia/neutropenia | ||
| Grade 3 | 5 | 24 |
| Grade 4 | 1 | 5 |
| Lymphopenia | 1 | 5 |
| Anemia | ||
| Grade 3 | 0 | 0 |
| Grade 4 | 1 | 5 |
| Increased partial thromboplastin time | 1 | 5 |
| Gemcitabine lung toxicity | 1 | 5 |
| Adverse event . | No. of patients (n = 21) . | % . |
|---|---|---|
| Sepsis | 2 | 10 |
| Duodenal perforation | 2 | 10 |
| Cystic fluid collection | 2 | 10 |
| Hyperlipasemia | 2 | 10 |
| Hyperamylasemia | 1 | 5 |
| Elevated liver tests | 1 | 5 |
| Fever | 1 | 5 |
| Leukopenia/neutropenia | ||
| Grade 3 | 5 | 24 |
| Grade 4 | 1 | 5 |
| Lymphopenia | 1 | 5 |
| Anemia | ||
| Grade 3 | 0 | 0 |
| Grade 4 | 1 | 5 |
| Increased partial thromboplastin time | 1 | 5 |
| Gemcitabine lung toxicity | 1 | 5 |